 <h1>TOBI Podhaler Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>tobramycin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about tobramycin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name TOBI Podhaler.</p><h2>In Summary</h2><p><b>Common side effects of TOBI Podhaler include:</b> voice disorder.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tobramycin: inhalation capsule, inhalation solution</i></p><p>Other dosage forms:</p><ul><li>injection solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, tobramycin (the active ingredient contained in TOBI Podhaler) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking tobramycin:</p><p>
<i>More common</i>
</p><ul>
<li>Bloody nose</li>
<li>difficulty with breathing</li>
<li>discoloration of sputum</li>
<li>fever</li>
<li>runny nose</li>
<li>sneezing</li>
<li>stuffy nose</li>
<li>voice changes</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chest pain</li>
<li>chills</li>
<li>continuing ringing or buzzing or other unexplained noise in the ears</li>
<li>hearing loss</li>
<li>painful or difficult urination</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>tightness in the chest</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Cough</li>
<li>fast heartbeat</li>
<li>hives, itching, skin rash</li>
<li>hoarseness</li>
<li>irritation</li>
<li>joint pain, stiffness or swelling</li>
<li>mouth or throat pain</li>
<li>noisy breathing</li>
<li>redness of the skin</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>troubled swallowing</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking tobramycin:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Blue lips, fingernails, or skin</li>
<li>dizziness or lightheadedness</li>
<li>drowsiness</li>
<li>feeling of constant movement of self or surroundings</li>
<li>irregular, fast or slow, or shallow breathing</li>
<li>sensation of spinning</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of tobramycin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>general feeling of discomfort or illness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Change or loss of taste</li>
<li>diarrhea</li>
<li>rash</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Decreased appetite</li>
<li>loss of voice</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tobramycin: compounding powder, inhalation capsule, inhalation solution, injectable powder for injection, injectable solution, intravenous solution</i></p><h3>General</h3><p>Inhalation Capsules: The most commonly reported side effects included cough, lung disorder, productive cough, and dyspnea.</p>
<p></p>
<p>Inhalation/nebulizer solution: The most commonly reported side effects included increased cough, pharyngitis, fever, and increased sputum.</p>
<p></p>
<p>Parenteral formulations: The most commonly reported serious side effects included hypersensitivity reactions, ototoxicity, and nephrotoxicity.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Inhalation Capsules:</p>
<p><b>Very common</b> (10% or more): Cough (up to 48.4%), lung disorder (up to 33.8%), productive cough (up to 18.2%), dyspnea (up to 15.6%), oropharyngeal pain (up to 14%), dysphonia (up to 13.6%), hemoptysis (up to 13%), pharyngolaryngeal pain (up to 10.9%)</p>
<p><b>Common</b> (1% to 10%): Bronchospasm, epistaxis, forced expiratory volume (FEV1) decreased, nasal congestion, pulmonary function test decreased, rales, throat irritation, upper respiratory tract infection, wheezing</p>
<p><b>Frequency not reported</b>: Cystic fibrosis exacerbation, pulmonary exacerbation, sputum discolored</p>
<p></p>
<p>Inhalation/nebulizer solution:</p>
<p><b>Very common</b> (10% or more): Cough increased (up to 50%), pharyngitis (up to 48%), sputum increased (up to 44%), dyspnea (up to 42%), rhinitis (up to 38%), lung disorder (up to 34%), cough (up to 31.1%), hemoptysis (up to 28%), lung function decreased (up to 29%), asthma (up to 28%), sputum discoloration (up to 25%), productive cough (up to 19.6%), sinusitis (up to 14%), upper respiratory tract infection (up to 14%), voice alteration (up to 13%), oropharyngeal pain (up to 10.5%)</p>
<p><b>Common</b> (1% to 10%): Dysphonia, epistaxis, FEV1 decreased, hyperventilation, hypoxia, laryngitis, lower respiratory tract infection, nasal congestion, nasal polyp, pulmonary function test decreased, rales, respiratory disorder, throat irritation, wheezing</p>
<p><b>Rare</b> (0.01% to 0.1%): Bronchospasm</p>
<p><b>Frequency not reported</b>: Pulmonary exacerbation</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Uncommon</b> (0.1% to 1%): Apnea, respiratory depression<sup>[Ref]</sup></p><h3>Other</h3><p>Ototoxicity, usually irreversible, was typically initially manifested by diminution of high-tone acuity, dizziness, hearing loss, roaring in the ears, tinnitus, and vertigo.  Patients receiving inhalation formulations with a history of prolonged treatment and/or receiving concomitant IV treatment with an aminoglycoside have developed hearing loss.  Ototoxicity may progress despite discontinuation in some patients.</p>
<p></p>
<p>Tinnitus was typically transient, usually resolved without discontinuation of treatment, and was associated with permanent hearing loss in some patients.<sup>[Ref]</sup></p><p>Inhalation Capsules:</p>
<p><b>Very common</b> (10% or more): Pyrexia (up to 15.6%)</p>
<p><b>Common</b> (1% to 10%): Deafness, deafness unilateral, hypoacusis, increased hearing loss, mild to moderate hearing loss, tinnitus</p>
<p><b>Frequency not reported</b>: Malaise</p>
<p></p>
<p>Inhalation/nebulizer solution:</p>
<p><b>Very common</b> (10% or more): Fever (up to 46%), asthenia (up to 44%), pain (up to 24%), pyrexia (up to 12.4%)</p>
<p><b>Common</b> (1% to 10%): Accidental injury, chills, malaise, otitis media, tinnitus</p>
<p><b>Uncommon</b> (0.1% to 1%): Deafness neurosensory, hypoacusis, mucosal dryness</p>
<p><b>Rare</b> (0.01% to 0.1%): Hearing loss</p>
<p><b>Very rare</b> (less than 0.01%): Ear disorder, ear pain</p>
<p><b>Frequency not reported</b>: Ototoxicity</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Common</b> (1% to 10%): Hearing loss/irreversible hearing loss, high frequency hearing loss, ototoxicity, roaring in the ears, tinnitus</p>
<p><b>Rare</b> (0.01% to 0.1%): Fever</p>
<p><b>Frequency not reported</b>: Transient cochlear toxicity<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Inhalation Capsules:</p>
<p><b>Very common</b> (10% or more): Headache (up to 11.4%)</p>
<p><b>Common</b> (1% to 10%): Aphonia, dysgeusia</p>
<p></p>
<p>Inhalation/nebulizer solution:</p>
<p><b>Very common</b> (10% or more): Headache (up to 34%), dysphonia (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, somnolence, taste perversion</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysgeusia, vertigo</p>
<p><b>Rare</b> (0.01% to 0.1%): Aphonia</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Common</b> (1% to 10%): Acute dizziness/dizziness, vertigo, vestibular dysfunction</p>
<p><b>Uncommon</b> (0.1% to 1%): Exacerbation of impairment of neuromuscular transmission, neuromuscular blocking effects</p>
<p><b>Rare</b> (0.01% to 0.1%): Acute brain syndrome, lethargy, neurotoxicity</p>
<p><b>Frequency not reported</b>: Headache<sup>[Ref]</sup></p><p>Acute brain syndrome occurred in an elderly patient approximately 4 days after starting treatment.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Inhalation Capsules:</p>
<p><b>Common</b> (1% to 10%): Chest discomfort</p>
<p></p>
<p>Inhalation/nebulizer solution:</p>
<p><b>Very common</b> (10% or more): Chest pain (up to 37%)</p>
<p><b>Common</b> (1% to 10%): Chest discomfort<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Inhalation Capsules:</p>
<p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting</p>
<p></p>
<p>Inhalation/nebulizer solution:</p>
<p><b>Very common</b> (10% or more): Abdominal pain (up to 27%)</p>
<p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting</p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal pain upper, glossitis, salivary hypersecretion</p>
<p><b>Rare</b> (0.01% to 0.1%): Mouth ulceration</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting</p>
<p><b>Rare</b> (0.01% to 0.1%): Stomatitis<sup>[Ref]</sup></p><h3>Renal</h3><p>Nephrotoxicity, demonstrated by rising BUN, NPN, serum creatinine, cylindruria, oliguria, and proteinuria, primarily occurred in patients with preexisting renal damage and in patients with normal renal function treated for longer periods and/or at higher doses than recommended.  Predisposing factors also included advanced age, dehydration, and concomitant use of other potentially nephrotoxic drugs.</p>
<p></p>
<p>Signs of renal failure included elevated serum creatinine and urea, and may be a rare complication in patients with cystic fibrosis.<sup>[Ref]</sup></p><p>Inhalation/nebulizer solution:</p>
<p><b>Frequency not reported</b>: Nephrotoxicity</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Common</b> (1% to 10%): Decreased glomerular filtration, elevated urea concentrations, increased blood urea nitrogen (BUN), increased nonprotein nitrogen (NPN), oliguria, reduced creatinine clearance, reduced renal function, renal function changes, reversible nephrotoxicity</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased serum creatinine</p>
<p><b>Rare</b> (0.01% to 0.1%): Acute renal failure, interstitial nephritis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Inhalation Capsules:</p>
<p><b>Common</b> (1% to 10%): Musculoskeletal chest pain</p>
<p></p>
<p>Inhalation/nebulizer solution:</p>
<p><b>Common</b> (1% to 10%): Back pain, musculoskeletal chest pain, myalgia</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Uncommon</b> (0.1% to 1%): Skeletal muscle weakness<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Inhalation Capsules:</p>
<p><b>Common</b> (1% to 10%): Rash</p>
<p></p>
<p>Inhalation/nebulizer solution:</p>
<p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Very rare</b> (less than 0.01%): Pruritus, urticaria</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Uncommon</b> (0.1% to 1%): Itching, maculopapular rash, urticaria</p>
<p><b>Rare</b> (0.01% to 0.1%): Exfoliative dermatitis, rash<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Parenteral formulations:</p>
<p><b>Common</b> (1% to 10%): Cylindruria, increased proteinuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Inhalation/nebulizer solution:</p>
<p><b>Common</b> (1% to 10%): Flu syndrome</p>
<p><b>Uncommon</b> (0.1% to 1%): Fungal infection, oral candidiasis<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Patients have developed a complex metabolic syndrome lasting approximately 2 to 8 weeks after administration of this drug; this syndrome was marked by hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypouricemia, and increased AST, ALT, serum bilirubin, and alkaline phosphatase.<sup>[Ref]</sup></p><p>Inhalation Capsules:</p>
<p><b>Common</b> (1% to 10%): Blood glucose increased</p>
<p></p>
<p>Inhalation/nebulizer solution:</p>
<p><b>Uncommon</b> (0.1% to 1%): Blood glucose increased</p>
<p><b>Rare</b> (0.01% to 0.1%): Anorexia</p>
<p><b>Postmarketing reports</b>: Decreased appetite</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Rare</b> (0.01% to 0.1%): Hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypouricemia, metabolic syndrome</p>
<p><b>Frequency not reported</b>: Increased serum lactate dehydrogenase<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Inhalation/nebulizer solution:</p>
<p><b>Common</b> (1% to 10%): Lymphadenopathy</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Rare</b> (0.01% to 0.1%): Anemia, chemotaxis inhibition, decreased platelet counts, decreased white cell counts, eosinophilia, granulocytopenia, inhibition of microbicidal activity of phagocytes, thrombocytopenia</p>
<p><b>Frequency not reported</b>: Leukocytosis, leukopenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Inhalation/nebulizer solution:</p>
<p><b>Uncommon</b> (0.1% to 1%): Transaminases increased</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Rare</b> (0.01% to 0.1%): Increased alkaline phosphatase, increased ALT, increased AST, increased serum bilirubin<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity reactions included anaphylaxis, angioedema, exfoliative dermatitis, and stomatitis.<sup>[Ref]</sup></p><p>Inhalation/nebulizer solution:</p>
<p><b>Very rare</b> (less than 0.01%): Hypersensitivity</p>
<p></p>
<p>Parenteral formulations:</p>
<p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis, angioedema, hypersensitivity reactions<sup>[Ref]</sup></p><h3>Local</h3><p>Parenteral formulations:</p>
<p><b>Rare</b> (0.01% to 0.1%): Pain (IM administration), thrombophlebitis (IV administration)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Parenteral formulations:</p>
<p><b>Frequency not reported</b>: Delirium, disorientation, mental confusion<sup>[Ref]</sup></p><p>Delirium was reversible after treatment was discontinued.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Nebcin (tobramycin)." Lilly, Eli and Company, Indianapolis, IN. </p><p id="ref_2">2. "Product Information. Tobi tobramycin solution for inhalation (tobramycin)" PathoGenesis, Skokie, IL. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about TOBI Podhaler (tobramycin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: aminoglycosides</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tobi Podhaler &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Tobi, Nebcin, Bethkis, Kitabis Pak</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Bacterial Infection</li>
<li>Cystic Fibrosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tobramycin: compounding powder, inhalation capsule, inhalation solution, injectable powder for injection, injectable solution, intravenous solution</i></p><h3>General</h3><p>Inhalation Capsules: The most commonly reported side effects included cough, lung disorder, productive cough, and dyspnea.</p><p></p><p>Inhalation/nebulizer solution: The most commonly reported side effects included increased cough, pharyngitis, fever, and increased sputum.</p><p></p><p>Parenteral formulations: The most commonly reported serious side effects included hypersensitivity reactions, ototoxicity, and nephrotoxicity.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Inhalation Capsules:</p><p><b>Very common</b> (10% or more): Cough (up to 48.4%), lung disorder (up to 33.8%), productive cough (up to 18.2%), dyspnea (up to 15.6%), oropharyngeal pain (up to 14%), dysphonia (up to 13.6%), hemoptysis (up to 13%), pharyngolaryngeal pain (up to 10.9%)</p><p><b>Common</b> (1% to 10%): Bronchospasm, epistaxis, forced expiratory volume (FEV1) decreased, nasal congestion, pulmonary function test decreased, rales, throat irritation, upper respiratory tract infection, wheezing</p><p><b>Frequency not reported</b>: Cystic fibrosis exacerbation, pulmonary exacerbation, sputum discolored</p><p></p><p>Inhalation/nebulizer solution:</p><p><b>Very common</b> (10% or more): Cough increased (up to 50%), pharyngitis (up to 48%), sputum increased (up to 44%), dyspnea (up to 42%), rhinitis (up to 38%), lung disorder (up to 34%), cough (up to 31.1%), hemoptysis (up to 28%), lung function decreased (up to 29%), asthma (up to 28%), sputum discoloration (up to 25%), productive cough (up to 19.6%), sinusitis (up to 14%), upper respiratory tract infection (up to 14%), voice alteration (up to 13%), oropharyngeal pain (up to 10.5%)</p><p><b>Common</b> (1% to 10%): Dysphonia, epistaxis, FEV1 decreased, hyperventilation, hypoxia, laryngitis, lower respiratory tract infection, nasal congestion, nasal polyp, pulmonary function test decreased, rales, respiratory disorder, throat irritation, wheezing</p><p><b>Rare</b> (0.01% to 0.1%): Bronchospasm</p><p><b>Frequency not reported</b>: Pulmonary exacerbation</p><p></p><p>Parenteral formulations:</p><p><b>Uncommon</b> (0.1% to 1%): Apnea, respiratory depression<sup>[Ref]</sup></p><h3>Other</h3><p>Ototoxicity, usually irreversible, was typically initially manifested by diminution of high-tone acuity, dizziness, hearing loss, roaring in the ears, tinnitus, and vertigo.  Patients receiving inhalation formulations with a history of prolonged treatment and/or receiving concomitant IV treatment with an aminoglycoside have developed hearing loss.  Ototoxicity may progress despite discontinuation in some patients.</p><p></p><p>Tinnitus was typically transient, usually resolved without discontinuation of treatment, and was associated with permanent hearing loss in some patients.<sup>[Ref]</sup></p><p>Inhalation Capsules:</p><p><b>Very common</b> (10% or more): Pyrexia (up to 15.6%)</p><p><b>Common</b> (1% to 10%): Deafness, deafness unilateral, hypoacusis, increased hearing loss, mild to moderate hearing loss, tinnitus</p><p><b>Frequency not reported</b>: Malaise</p><p></p><p>Inhalation/nebulizer solution:</p><p><b>Very common</b> (10% or more): Fever (up to 46%), asthenia (up to 44%), pain (up to 24%), pyrexia (up to 12.4%)</p><p><b>Common</b> (1% to 10%): Accidental injury, chills, malaise, otitis media, tinnitus</p><p><b>Uncommon</b> (0.1% to 1%): Deafness neurosensory, hypoacusis, mucosal dryness</p><p><b>Rare</b> (0.01% to 0.1%): Hearing loss</p><p><b>Very rare</b> (less than 0.01%): Ear disorder, ear pain</p><p><b>Frequency not reported</b>: Ototoxicity</p><p></p><p>Parenteral formulations:</p><p><b>Common</b> (1% to 10%): Hearing loss/irreversible hearing loss, high frequency hearing loss, ototoxicity, roaring in the ears, tinnitus</p><p><b>Rare</b> (0.01% to 0.1%): Fever</p><p><b>Frequency not reported</b>: Transient cochlear toxicity<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Inhalation Capsules:</p><p><b>Very common</b> (10% or more): Headache (up to 11.4%)</p><p><b>Common</b> (1% to 10%): Aphonia, dysgeusia</p><p></p><p>Inhalation/nebulizer solution:</p><p><b>Very common</b> (10% or more): Headache (up to 34%), dysphonia (up to 13%)</p><p><b>Common</b> (1% to 10%): Dizziness, somnolence, taste perversion</p><p><b>Uncommon</b> (0.1% to 1%): Dysgeusia, vertigo</p><p><b>Rare</b> (0.01% to 0.1%): Aphonia</p><p></p><p>Parenteral formulations:</p><p><b>Common</b> (1% to 10%): Acute dizziness/dizziness, vertigo, vestibular dysfunction</p><p><b>Uncommon</b> (0.1% to 1%): Exacerbation of impairment of neuromuscular transmission, neuromuscular blocking effects</p><p><b>Rare</b> (0.01% to 0.1%): Acute brain syndrome, lethargy, neurotoxicity</p><p><b>Frequency not reported</b>: Headache<sup>[Ref]</sup></p><p>Acute brain syndrome occurred in an elderly patient approximately 4 days after starting treatment.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Inhalation Capsules:</p><p><b>Common</b> (1% to 10%): Chest discomfort</p><p></p><p>Inhalation/nebulizer solution:</p><p><b>Very common</b> (10% or more): Chest pain (up to 37%)</p><p><b>Common</b> (1% to 10%): Chest discomfort<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Inhalation Capsules:</p><p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting</p><p></p><p>Inhalation/nebulizer solution:</p><p><b>Very common</b> (10% or more): Abdominal pain (up to 27%)</p><p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal pain upper, glossitis, salivary hypersecretion</p><p><b>Rare</b> (0.01% to 0.1%): Mouth ulceration</p><p></p><p>Parenteral formulations:</p><p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting</p><p><b>Rare</b> (0.01% to 0.1%): Stomatitis<sup>[Ref]</sup></p><h3>Renal</h3><p>Nephrotoxicity, demonstrated by rising BUN, NPN, serum creatinine, cylindruria, oliguria, and proteinuria, primarily occurred in patients with preexisting renal damage and in patients with normal renal function treated for longer periods and/or at higher doses than recommended.  Predisposing factors also included advanced age, dehydration, and concomitant use of other potentially nephrotoxic drugs.</p><p></p><p>Signs of renal failure included elevated serum creatinine and urea, and may be a rare complication in patients with cystic fibrosis.<sup>[Ref]</sup></p><p>Inhalation/nebulizer solution:</p><p><b>Frequency not reported</b>: Nephrotoxicity</p><p></p><p>Parenteral formulations:</p><p><b>Common</b> (1% to 10%): Decreased glomerular filtration, elevated urea concentrations, increased blood urea nitrogen (BUN), increased nonprotein nitrogen (NPN), oliguria, reduced creatinine clearance, reduced renal function, renal function changes, reversible nephrotoxicity</p><p><b>Uncommon</b> (0.1% to 1%): Increased serum creatinine</p><p><b>Rare</b> (0.01% to 0.1%): Acute renal failure, interstitial nephritis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Inhalation Capsules:</p><p><b>Common</b> (1% to 10%): Musculoskeletal chest pain</p><p></p><p>Inhalation/nebulizer solution:</p><p><b>Common</b> (1% to 10%): Back pain, musculoskeletal chest pain, myalgia</p><p></p><p>Parenteral formulations:</p><p><b>Uncommon</b> (0.1% to 1%): Skeletal muscle weakness<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Inhalation Capsules:</p><p><b>Common</b> (1% to 10%): Rash</p><p></p><p>Inhalation/nebulizer solution:</p><p><b>Common</b> (1% to 10%): Rash</p><p><b>Very rare</b> (less than 0.01%): Pruritus, urticaria</p><p></p><p>Parenteral formulations:</p><p><b>Uncommon</b> (0.1% to 1%): Itching, maculopapular rash, urticaria</p><p><b>Rare</b> (0.01% to 0.1%): Exfoliative dermatitis, rash<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Parenteral formulations:</p><p><b>Common</b> (1% to 10%): Cylindruria, increased proteinuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Inhalation/nebulizer solution:</p><p><b>Common</b> (1% to 10%): Flu syndrome</p><p><b>Uncommon</b> (0.1% to 1%): Fungal infection, oral candidiasis<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Patients have developed a complex metabolic syndrome lasting approximately 2 to 8 weeks after administration of this drug; this syndrome was marked by hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypouricemia, and increased AST, ALT, serum bilirubin, and alkaline phosphatase.<sup>[Ref]</sup></p><p>Inhalation Capsules:</p><p><b>Common</b> (1% to 10%): Blood glucose increased</p><p></p><p>Inhalation/nebulizer solution:</p><p><b>Uncommon</b> (0.1% to 1%): Blood glucose increased</p><p><b>Rare</b> (0.01% to 0.1%): Anorexia</p><p><b>Postmarketing reports</b>: Decreased appetite</p><p></p><p>Parenteral formulations:</p><p><b>Rare</b> (0.01% to 0.1%): Hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypouricemia, metabolic syndrome</p><p><b>Frequency not reported</b>: Increased serum lactate dehydrogenase<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Inhalation/nebulizer solution:</p><p><b>Common</b> (1% to 10%): Lymphadenopathy</p><p></p><p>Parenteral formulations:</p><p><b>Rare</b> (0.01% to 0.1%): Anemia, chemotaxis inhibition, decreased platelet counts, decreased white cell counts, eosinophilia, granulocytopenia, inhibition of microbicidal activity of phagocytes, thrombocytopenia</p><p><b>Frequency not reported</b>: Leukocytosis, leukopenia<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Inhalation/nebulizer solution:</p><p><b>Uncommon</b> (0.1% to 1%): Transaminases increased</p><p></p><p>Parenteral formulations:</p><p><b>Rare</b> (0.01% to 0.1%): Increased alkaline phosphatase, increased ALT, increased AST, increased serum bilirubin<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity reactions included anaphylaxis, angioedema, exfoliative dermatitis, and stomatitis.<sup>[Ref]</sup></p><p>Inhalation/nebulizer solution:</p><p><b>Very rare</b> (less than 0.01%): Hypersensitivity</p><p></p><p>Parenteral formulations:</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis, angioedema, hypersensitivity reactions<sup>[Ref]</sup></p><h3>Local</h3><p>Parenteral formulations:</p><p><b>Rare</b> (0.01% to 0.1%): Pain (IM administration), thrombophlebitis (IV administration)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Parenteral formulations:</p><p><b>Frequency not reported</b>: Delirium, disorientation, mental confusion<sup>[Ref]</sup></p><p>Delirium was reversible after treatment was discontinued.<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Nebcin (tobramycin)." Lilly, Eli and Company, Indianapolis, IN. </p><p id="ref_2">2. "Product Information. Tobi tobramycin solution for inhalation (tobramycin)" PathoGenesis, Skokie, IL. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about TOBI Podhaler (tobramycin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: aminoglycosides</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tobi Podhaler &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bacterial Infection</li>
<li>Cystic Fibrosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>